Kovina Therapeutics Received NCI Grant for HPV Therapy
Indianapolis-based researchers secured funding to advance a potential new oral treatment for HPV-related cancers.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you believe government funding for experimental cancer research programs provides good value for taxpayers?
Kovina Therapeutics was awarded a $2.3 million grant from the National Cancer Institute to support development of an oral small molecule therapy. This funding will advance research aimed at addressing HPV-linked cancers, which affect roughly 39,300 people annually in the United States.
Why it matters
By targeting the HPV E6 oncoprotein, this therapy aims to restore the body's natural p53 tumor suppressor activity. This research seeks to provide a new therapeutic option for the significant number of patients affected by HPV-driven malignancies.
The National Cancer Institute awarded a $2.3 million Direct-to-Phase II SBIR grant to support a two-year program focused on IND-enabling development. The research aims to advance an oral small molecule candidate targeting the HPV E6 oncoprotein, though it remains in preclinical development.
The players
Kovina Therapeutics
An Indianapolis-based biotechnology company developing small molecule therapeutics for HPV-associated diseases.
National Cancer Institute
The federal agency responsible for cancer research, training, and health information dissemination in the United States.
The details
The experimental therapy is designed to inhibit the HPV E6 oncoprotein, a protein that typically facilitates the degradation of p53, a critical tumor suppressor in the human body. By preventing this interaction, the drug aims to restore p53 function, potentially stopping the progression of cancer cells. The grant funds the necessary chemistry, manufacturing, and control studies, as well as pharmacology and toxicology research required to file an Investigational New Drug application.
Timeline
September 24, 2026: Kovina Therapeutics announced the receipt of the NCI grant.
Two-year period: The duration of the NCI SBIR award funding.
Health Landscape
This project represents a specific effort within the broader oncology landscape to transition away from traditional systemic treatments toward targeted molecular therapies. It follows the established mechanism of the National Cancer Institute SBIR/STTR program to move early-stage biotechnology toward Investigational New Drug status.
This development is in the preclinical stage, meaning it is not yet available as a treatment option for patients. Individuals with concerns regarding HPV-related risks or screening should schedule a conversation with their primary care physician to discuss current preventative care.
The takeaway
This grant marks a step forward in research for targeted HPV therapies, which may one day offer an alternative to existing treatments. Patients concerned about cancer prevention should focus on maintaining recommended HPV vaccination and screening schedules advised by their doctors.
Further reading
For more information on current treatment trends, visit the Cancer section.
Live Poll
Do you believe government funding for experimental cancer research programs provides good value for taxpayers?
